Jamie Caudill, MD
Internal Medicine · Mobile, ALNPI 1699095182
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,515 of the $51,868 with a category attached, or 93.5%. Novo Nordisk accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $37,932, more than ten times the $125 reported in 2021. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $489.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$52K
- AbbVie$25
What the payments were for
- Speaking & faculty fees$48,51594%
- Travel & lodging$1,4693%
- Food & beverage$1,8854%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 105 | $51,843 |
| AbbVie | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,868 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 35 | $36,326 |
| EliquisApixaban | 12 | $7,253 |
| Ondansetron OdtOndansetron | 48 | $518 |
| Cefdinir | 40 | $398 |
| Prednisone | 41 | $315 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $308 |
| Pantoprazole Sodium | 52 | $242 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $198 |
| Levofloxacin | 43 | $175 |
| Montelukast Sodium | 34 | $160 |
| Azithromycin | 28 | $135 |
| Famotidine | 12 | $128 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $114 |
| Metronidazole | 11 | $88 |
| Sucralfate | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Mobile
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Bobby WrightsMobile$89K
- Rahel AzizMobile$67K
- Lin LiMobile$45K
- Edward CarlosMobile$26K
- Donald SandersMobile$23K
- Amy StrassburgMobile$18K
- Roger AlvaradoMobile$18K
- Daniel PolanskyMobile$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.